Reconciled ClinicalTrials.gov v2 Protocol Specification
| Protocol Field | Verified Registry Value |
|---|---|
| NCT Identifier | NCT07493304 |
| Consolidated Lead Sponsor | Regeneron Pharmaceuticals |
| Therapeutic Condition Cohort | Oncology and Hematology |
| Clinical Trial Phase | Phase III |
| Overall Recruitment Status | RECRUITING |
| Registered Enrollment | 1,600 participants (ESTIMATED) |
| Registered Start Date | 2026-08-26 |
| WhyStopped Classification | Not Stopped |
Named U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Site Profile |
|---|---|---|
| Memorial Sloan Kettering Cancer Center | New York, NY | Open Hospital Dossier -> |
| Inje University Haeundae Paik Hospital | Busan, South Korea | Open Hospital Dossier -> |
| Yonsei University Health System, Severance Hospital | Seoul, South Korea | Open Hospital Dossier -> |
| Samsung Medical Center | Seoul, South Korea | Open Hospital Dossier -> |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Regeneron Pharmaceuticals across sibling Meru public-data platforms.
Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.